In recent trading session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) saw 1.81 million shares changing hands at last check today with its beta currently measuring 1.09. Company’s recent per share price level of $0.35 trading at -$0.03 or -7.11% at last check today assigns it a market valuation of $127.89M. That most recent trading price of LXRX’s stock is at a discount of -651.43% from its 52-week high price of $2.63 and is indicating a premium of 20.0% from its 52-week low price of $0.28. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 15.21 million shares which gives us an average trading volume of 6.63 million if we extend that period to 3-months.
For Lexicon Pharmaceuticals Inc (LXRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.17. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.1 in the current quarter.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Upright in the red during last session for losing -7.11%, in the last five days LXRX remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $0.35 price level, adding 14.4% to its value on the day. Lexicon Pharmaceuticals Inc’s shares saw a change of -52.09% in year-to-date performance and have moved -3.78% in past 5-day. Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) showed a performance of -49.09% in past 30-days. Number of shares sold short was 47.46 million shares which calculate 11.94 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 94.17% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -1614.29% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1614.29% for stock’s current value.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
This year revenue growth is estimated to fall -72.33% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.26M for the same. And 4 analysts are in estimates of company making revenue of 1.33M in the next quarter. Company posted 1.13M and 1.65M of sales in current and next quarters respectively a year earlier. In 2025, company’s earnings growth rate is likely to be around 41.27% while estimates for its earnings growth in next 5 years are of 22.79%.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Insiders are in possession of 1.19% of company’s total shares while institution are holding 84.10 percent of that, with stock having share float percentage of 85.11%. Investors also watch the number of corporate investors in a company very closely, which is 84.10% institutions for Lexicon Pharmaceuticals Inc that are currently holding shares of the company. ARTAL GROUP S.A. is the top institutional holder at LXRX for having 175.1 million shares of worth $294.17 million. And as of 2024-06-30, it was holding 56.3318 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 38.69 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.7656 of outstanding shares, having a total worth of $64.99 million.
On the other hand, Fidelity Growth Company Fund and Fidelity Growth Company K6 Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 16.9 shares of worth $6.08 million or 4.67% of the total outstanding shares. The later fund manager was in possession of 5.5 shares on Dec 31, 2024 , making its stake of worth around $1.98 million in the company or a holder of 1.52% of company’s stock.
